1 Guidance

1 Guidance

1.1

Current evidence on the efficacy and safety of percutaneous cryotherapy for renal cancer is adequate to support the use of this procedure provided that normal arrangements are in place for clinical governance, consent and audit.

1.2

This procedure should only be offered after assessment by a specialist urological cancer multidisciplinary team.

1.3

NICE encourages collection and publication of data on the outcomes of this procedure in the long term. Further research should compare the long-term outcomes of cryotherapy with those of other treatments for renal cancer.